CorMedix (NASDAQ:CRMD) Releases Earnings Results

CorMedix (NASDAQ:CRMD) announced its quarterly earnings results on Thursday. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.70), FiscalAI reports. CorMedix had a return on equity of 51.77% and a net margin of 75.83%.The company had revenue of $128.62 million for the quarter, compared to analyst estimates of $127.02 million. During the same quarter last year, the company posted $0.22 earnings per share. The firm’s quarterly revenue was up 312.1% on a year-over-year basis.

Here are the key takeaways from CorMedix’s conference call:

• Acquisition and synergies: CorMedix closed the Melinta acquisition in Q3 2025 and says it achieved its targeted $35 million of synergies in Q4 while DefenCath reached peak sales of just under $260 million.
• Guidance affirmed: The company reaffirmed 2026 DefenCath guidance of $150–170M, 2027 DefenCath guidance of $100–125M, and full-year 2026 revenue and Adjusted EBITDA guidance of $300–320M and $100–125M, respectively.
• TDAPA transition risk: On July 1, 2026 TDAPA reimbursement shifts to a bundled add-on which management expects will cause price erosion in Q3–Q4 2026; negotiations with customers are ongoing and 2027 reimbursement may improve but near-term revenue concentration is expected to be front‑loaded into H1 2026.
• Pipeline catalyst — REZZAYO: Top-line data from the phase 3 ReSPECT study for REZZAYO prophylaxis are expected in Q2 2026, and management estimates the REZZAYO opportunity at roughly $2.5 billion across indications.
• Strong financial position: Q4 net revenue was $128.6M (DefenCath $91.2M, Melinta $37.4M), full-year pro forma revenue was $401.3M, cash and short-term investments totaled $148.5M, and the company has an active share repurchase program.

CorMedix Trading Down 8.4%

Shares of CorMedix stock traded down $0.60 during midday trading on Thursday, reaching $6.52. The company had a trading volume of 1,999,518 shares, compared to its average volume of 2,801,656. The stock has a fifty day moving average price of $8.29 and a 200 day moving average price of $10.43. CorMedix has a fifty-two week low of $5.60 and a fifty-two week high of $17.43. The firm has a market cap of $513.71 million, a PE ratio of 3.17 and a beta of 1.31. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.94 and a quick ratio of 1.73.

CorMedix declared that its Board of Directors has initiated a share buyback program on Monday, February 2nd that authorizes the company to buyback $75.00 million in shares. This buyback authorization authorizes the company to purchase up to 12.3% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at CorMedix

In other news, CEO Joseph Todisco sold 30,000 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. Following the sale, the chief executive officer directly owned 509,496 shares of the company’s stock, valued at approximately $6,113,952. This represents a 5.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steven W. Lefkowitz sold 40,000 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the sale, the director owned 80,498 shares of the company’s stock, valued at approximately $956,316.24. This trade represents a 33.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 90,000 shares of company stock valued at $1,095,200. 3.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CorMedix

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Trust Advisors LP bought a new stake in CorMedix in the second quarter valued at $142,000. Russell Investments Group Ltd. raised its stake in CorMedix by 83.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 12,040 shares of the company’s stock worth $140,000 after buying an additional 5,487 shares during the period. Wright Wealth LLC bought a new position in CorMedix in the fourth quarter worth approximately $138,000. Vestcor Inc bought a new stake in shares of CorMedix during the third quarter valued at approximately $138,000. Finally, Equitable Holdings Inc. acquired a new position in shares of CorMedix during the third quarter worth approximately $128,000. Institutional investors and hedge funds own 34.18% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Needham & Company LLC reduced their price objective on CorMedix from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Zacks Research cut CorMedix from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 10th. HC Wainwright lowered their price objective on CorMedix from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Wall Street Zen lowered shares of CorMedix from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Royal Bank Of Canada set a $13.00 target price on shares of CorMedix and gave the stock an “outperform” rating in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.86.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.